Loading...
Market
Canadian Healthcare Providers Prescribing Wegovy for Heart Attack Risk by End of 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Survey data or reports from Canadian healthcare associations
Story
Canada Approves Wegovy as First Treatment to Reduce Nonfatal Heart Attack Risk on November 27, 2024
Nov 27, 2024, 06:47 PM
Canada's health regulator has granted approval for Novo Nordisk's weight loss drug, Wegovy, aimed at reducing the risk of nonfatal heart attacks or myocardial infarctions in certain adults. This marks Wegovy as the first treatment in Canada to simultaneously address obesity and the risk of heart-related conditions for adults with established cardiovascular disease. The announcement was made by the Danish drugmaker on November 27, 2024, highlighting the drug's potential in combating significant health risks associated with obesity.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
Above 150,000 • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Yes • 50%
No • 50%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
Yes • 50%
No • 50%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%